Phil Vickers

Phil Vickers is President and CEO of Solu Therapeutics, a Boston clinical-stage biotech building small-molecule 'chimeras' that ferry cytotoxic payloads to disease-driving cells. He arrived in September 2023 after runs at Faze Medicines and Northern Biologics, and R&D leadership at Shire, Boehringer-Ingelheim, Pfizer and Merck. In April 2025 he closed a $41M Series A with Eli Lilly, Pappas Capital and the Leukemia & Lymphoma Society and dosed the first patient in a Phase 1 trial of STX-0712 for CMML.